101 related articles for article (PubMed ID: 3030206)
1. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.
García-Rafanell J; Ramis J; Gomez L; Forn J
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):155-65. PubMed ID: 3030206
[TBL] [Abstract][Full Text] [Related]
2. Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
de la Cruz JP; Pavia J; Bellido I; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Jun; 10(6):363-7. PubMed ID: 3412046
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.
González-Correa JA; Arrebola MM; Ureña IM; Ruiz-Villafranca D; Muñoz-Marín J; Guerrero A; Sánchez de la Cuesta F; De La Cruz JP
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):81-8. PubMed ID: 15602657
[TBL] [Abstract][Full Text] [Related]
5. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation.
Bayón Y; Alonso A; Sánchez Crespo M
Br J Pharmacol; 1999 Mar; 126(6):1359-66. PubMed ID: 10217529
[TBL] [Abstract][Full Text] [Related]
6. Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats.
De Castellarnau C; Sancho MJ; Vila L; Albors M; Rutllant ML
Prostaglandins Leukot Essent Fatty Acids; 1988 Feb; 31(2):83-9. PubMed ID: 3128800
[TBL] [Abstract][Full Text] [Related]
7. Platelet antiaggregatory effect of triflusal in human whole blood.
de la Cruz JP; Pavia J; Bellido I; González MC; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):273-7. PubMed ID: 3386335
[TBL] [Abstract][Full Text] [Related]
8. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
De La Cruz JP; Villalobos MA; García PJ; Smith-Agreda JM; Sánchez de la Cuesta F
Eur J Clin Pharmacol; 1995; 47(6):497-502. PubMed ID: 7768251
[TBL] [Abstract][Full Text] [Related]
9. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cardiac hypertrophy by triflusal (4-trifluoromethyl derivative of salicylate) and its active metabolite.
Planavila A; Rodríguez-Calvo R; de Arriba AF; Sánchez RM; Laguna JC; Merlos M; Vazquez-Carrera M
Mol Pharmacol; 2006 Apr; 69(4):1174-81. PubMed ID: 16421291
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils.
Sánchez de Miguel L; Casado S; Farré J; García-Durán M; Rico LA; Montón M; Romero J; Bellver T; Sierra MP; Guerra JI; Mata P; Esteban A; López-Farré A
Eur J Pharmacol; 1998 Feb; 343(1):57-65. PubMed ID: 9551715
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
Kim SW; Choi KJ; Park JY; Yoon SH; Lee JK
Neurosci Lett; 2017 Mar; 643():59-64. PubMed ID: 28189746
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of triflusal after single and repeated doses in man.
Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J
Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anesthetized rats.
Gómez L; García Rafanell J; Forn J
Methods Find Exp Clin Pharmacol; 1987 Jan; 9(1):13-7. PubMed ID: 3106730
[TBL] [Abstract][Full Text] [Related]
16. Thrombin decreases platelet cyclic AMP in the absence of prostaglandin synthesis.
Lagarde M; Dechavanne M
Biomedicine; 1977 Apr; 27(3):110-2. PubMed ID: 196696
[TBL] [Abstract][Full Text] [Related]
17. Photochemistry of 2-hydroxy-4-trifluoromethylbenzoic acid, major metabolite of the photosensitizing platelet antiaggregant drug triflusal.
Boscá F; Cuquerella MC; Marín ML; Miranda MA
Photochem Photobiol; 2001 May; 73(5):463-8. PubMed ID: 11367565
[TBL] [Abstract][Full Text] [Related]
18. Effects of acetylsalicylic acid on human platelet function in vivo at salicylate steady state.
Simrock R; Missalla A; Schwidtal P; Lischke V; Breddin HK
Thromb Haemost; 1984 Apr; 51(2):269-71. PubMed ID: 6740559
[TBL] [Abstract][Full Text] [Related]
19. The effect of acetylsalicylic acid/salicylic acid mixtures on acetylcholinesterase activity in vitro.
Leeling J; Bare J; Medon P
Arzneimittelforschung; 1978; 28(10):1727-8. PubMed ID: 582677
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
Ramis J; Mis R; Forn J
Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
